Related Experiment Videos

Clinical potential of a new HIV protease inhibitor

S Chapman¹, J Peterkin, B Quart

¹Agouron Pharmaceuticals, La Jolla, CA.

Journal of the International Association of Physicians in AIDS Care

|June 1, 1995

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment.

HIV medicine·2020

Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration - a comprehensive meeting report.

HIV medicine·2016

Lytic to temperate switching of viral communities.

Nature·2016

The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz.

Clinical pharmacology and therapeutics·2009

Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population.

HIV medicine·2009

Pharmacokinetics of acetyl-L-carnitine given in single or multiple doses to HIV-1 Infected patients with toxic peripheral polyneuropathy.

The open AIDS journal·2008

See all related articles